<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Meloxicam: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Meloxicam: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Meloxicam: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10295" href="/d/html/10295.html" rel="external">see "Meloxicam: Drug information"</a> and <a class="drug drug_patient" data-topicid="10836" href="/d/html/10836.html" rel="external">see "Meloxicam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709031"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiovascular thrombotic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Meloxicam is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious gastrointestinal bleeding, ulcerations, and perforation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">NSAIDs cause an increased risk of serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F191887"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anjeso [DSC];</li>
<li>Mobic [DSC];</li>
<li>Qmiiz ODT [DSC];</li>
<li>Vivlodex [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867439"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Meloxicam [DSC];</li>
<li>APO-Meloxicam;</li>
<li>Auro-Meloxicam;</li>
<li>PMS-Meloxicam;</li>
<li>TEVA-Meloxicam</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1023678"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Nonopioid</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F935401"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dose form information:</b> Orally disintegrating tablets, capsules, tablets, and oral suspension do not have equivalent systemic exposure and are not interchangeable, even if the total milligram strength is the same; do not substitute similar dose strengths of other meloxicam products.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA): Note:</b> To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time; adjust dose to patient's clinical needs; higher doses have not demonstrated additional benefit in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: Oral: 0.125 mg/kg once daily; maximum dose: 7.5 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablets (Qmiiz ODT): <b>Note:</b> Qmiiz ODT has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents weighing ≥60 kg: Oral: 7.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents weighing ≥60 kg: Oral: 7.5 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130269"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe renal impairment: Use is not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Not dialyzable; additional doses are not required after hemodialysis; maximum dose: 7.5 mg/dose.</p>
<p style="text-indent:-2em;margin-left:2em;">KDIGO guidelines provide the following recommendations for NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F51130270"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustments are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution; meloxicam is significantly metabolized in the liver.</p></div>
<div class="block doa drugH1Div" id="F191892"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10295" href="/d/html/10295.html" rel="external">see "Meloxicam: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Safety: </b>Avoid or use with caution in patients at risk for or with existing cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis due to greater risk for adverse events. Consider proton pump inhibitor coadministration in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high meloxicam doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-19017521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-19017521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Use the lowest effective dose for the shortest duration of time. Lower doses (eg, ≤7.5 mg/day) may be relatively COX-2 selective, but this relative selectivity is lost at higher doses (eg, 15 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Capsules, orally disintegrating tablets, oral suspension, and tablets do not have equivalent systemic exposure and are not interchangeable, even if the total milligram strength is the same.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c28c7a4-d701-4dda-9ca7-b4ba7882a2bb">Acute pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to slow onset, other oral nonsteroidal anti-inflammatory drugs (NSAIDs) are generally preferred; however, some experts use for postoperative pain management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Joshi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Joshi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Capsule:</b>
<b>Oral (off-label route): </b>5 mg to 10 mg once daily; maximum dose: 10 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mariano.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mariano.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Orally disintegrating tablet (Omiiz ODT): Oral (off-label route):</b> 7.5 mg to 15 mg once daily; maximum dose: 15 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mariano.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mariano.1'])">Ref</a></span>). <b>Note:</b> Qmiiz ODT has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b>
<b>Oral (off-label route): </b>7.5 mg to 15 mg once daily; maximum dose: 15 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mariano.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mariano.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b>
<b>Oral (off-label route): </b>7.5 mg to 15 mg once daily; maximum dose: 15 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mariano.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mariano.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> 15 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15110132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15110132'])">Ref</a></span>); initiate within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de72da14-7984-4455-9145-f85bde10917f">Osteoarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Capsule: Oral:</b> Initial: 5 mg once daily; may increase to a maximum of 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Orally disintegrating tablet:</b>
<b>Oral:</b> Initial: 7.5 mg once daily; may increase to a maximum of 15 mg once daily. <b>Note:</b> Qmiiz ODT has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b>
<b>Oral:</b> Initial: 7.5 mg once daily; may increase to a maximum of 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b>
<b>Oral:</b> Initial: 7.5 mg once daily; may increase to a maximum of 15 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Orally disintegrating tablet:</b>
<b>Oral:</b> Initial: 7.5 mg once daily; may increase to a maximum of 15 mg once daily. <b>Note:</b> Qmiiz ODT has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b>
<b>Oral:</b> Initial: 7.5 mg once daily; may increase to a maximum of 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b>
<b>Oral:</b> Initial: 7.5 mg once daily; may increase to a maximum of 15 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991781"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: Use is not recommended; contraindicated in patients who are at risk for renal failure due to volume depletion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8630639','lexi-content-ref-9056050','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8630639','lexi-content-ref-9056050','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;30 to &lt;60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8630639','lexi-content-ref-9056050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8630639','lexi-content-ref-9056050'])">Ref</a></span>). Use of analgesics other than nonsteroidal anti-inflammatory drugs may be preferred. If necessary, use the lowest effective dose for the shortest duration possible; avoid in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, elderly, or taking concurrent nephrotoxic medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≤30 mL/minute: Avoid use due to increased risk of acute kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9010704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9010704'])">Ref</a></span>): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988940"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Mild to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution to avoid adverse effects and discontinue if hepatic function worsens.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution to avoid adverse effects and discontinue if hepatic function worsens.</p></div>
<div class="block arsc drugH1Div" id="F56791132"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious adverse cardiovascular (CV) events, including <b>acute myocardial infarction</b> (MI), <b>cerebrovascular accident</b>, and CV death. New-onset <b>hypertension</b> or exacerbation of hypertension may occur with NSAID use which may also contribute to an increased risk of CV events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020251','lexi-content-ref-31937550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020251','lexi-content-ref-31937550'])">Ref</a></span>). New-onset or exacerbation of <b>heart failure</b> may also occur with nonselective NSAIDs (eg, naproxen), cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs), and relatively selective COX-2 inhibitors (eg, meloxicam), resulting in an increased risk of hospitalizations for heart failure and death in patients with heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23747642','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23747642','lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data collected by the Coxib and traditional NSAID Trialists’ (CNT) Collaborative has shown that use of COX-2 selective NSAIDs, including celecoxib, may increase the risk of major vascular events as compared to nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390'])">Ref</a></span>); however, data from the PRECISION trial showed no difference with regards to risk between celecoxib, naproxen, or ibuprofen after a treatment duration of therapy of ~3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959716'])">Ref</a></span>). A nested matched case-control trial found that use of meloxicam resulted in a 38% increase in the risk of MI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29030657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29030657'])">Ref</a></span>). Additional trial and registry data are also conflicted with regards to the comparative risk of CV events among the COX-2 selective and nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15705456','lexi-content-ref-18541831','lexi-content-ref-15947398','lexi-content-ref-21224324','lexi-content-ref-12020179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15705456','lexi-content-ref-18541831','lexi-content-ref-15947398','lexi-content-ref-21224324','lexi-content-ref-12020179'])">Ref</a></span>). However, data in those with established heart disease consistently reveals an increased risk of harm with NSAID use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19171810','lexi-content-ref-24280110','lexi-content-ref-21555710','lexi-content-ref-24690187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19171810','lexi-content-ref-24280110','lexi-content-ref-21555710','lexi-content-ref-24690187'])">Ref</a></span>). The FDA states that there is insufficient data to determine if risk of MI or stroke is definitely higher or lower for any particular NSAID as compared to another (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; inhibition of COX-2 by NSAIDs results in a reduction in the production of prostaglandin I<sub>2</sub> (prostacyclin) in the vascular endothelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11509629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11509629'])">Ref</a></span>); animal studies have shown that reduced prostacyclin activity may result in a predisposition to vascular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964481'])">Ref</a></span>). In addition, prostaglandins inhibit sodium resorption in the thick ascending loop of Henle and collecting tubule; therefore, a reduction in prostaglandin synthesis by NSAIDs may cause sodium and fluid retention and result in hypertension and decreased efficacy of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23747642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23747642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increased risk may be apparent within the first weeks following initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-21555710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-21555710'])">Ref</a></span>); longer duration of therapy may further increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (especially with regards to CV thrombotic risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use and frequent use (eg, ≥22 days per month) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16534006','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16534006','lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiovascular disease (CVD) or presence of risk factors for CVD, including use following coronary artery bypass graft surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note:</b> Relative risk appears to be similar in those with and without known CVD or risk factors for CVD; however, absolute incidence of serious CV thrombotic events appears to be higher in patients with known CVD or risk factors for CVD due to an increased baseline risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious gastrointestinal (GI) adverse events, including GI inflammation<b>, gastrointestinal hemorrhage</b>, <b>gastrointestinal ulcer</b>, and <b>gastrointestinal perforation</b>; severity may range from asymptomatic to fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390','lexi-content-ref-31937550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390','lexi-content-ref-31937550'])">Ref</a></span>). Selective cyclooxygenase (COX)-2 NSAIDs, including relatively selective COX-2 inhibitors (eg, meloxicam), appear to be associated with a lower risk of significant GI adverse events as compared to nonselective NSAIDs; the concomitant use of low-dose aspirin therapy may diminish the safety advantage of COX-2 selective NSAIDs over nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390','lexi-content-ref-9783757','lexi-content-ref-20955443','lexi-content-ref-12810929','lexi-content-ref-17556027','lexi-content-ref-10628593','lexi-content-ref-15234645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390','lexi-content-ref-9783757','lexi-content-ref-20955443','lexi-content-ref-12810929','lexi-content-ref-17556027','lexi-content-ref-10628593','lexi-content-ref-15234645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; inhibition of COX-1 by NSAIDs results in a reduction in the production of mucosal-protective prostaglandin E<sub>2</sub>. COX-2 selective NSAIDs may block COX-1 in the GI tract, albeit to a lesser degree as compared to nonselective NSAIDs, and therefore have the ability to cause damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9626023','lexi-content-ref-10377455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9626023','lexi-content-ref-10377455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; GI events can occur at any time during use and without warning symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, meloxicam 15 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17556027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17556027'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of peptic ulcer disease and/or GI bleeding</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of agents known to increase the risk of GI bleeding (eg, aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>); anticoagulants, corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443','lexi-content-ref-2012355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443','lexi-content-ref-2012355'])">Ref</a></span>); selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid <i>Helicobacter pylori</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16469671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16469671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced liver disease/cirrhosis</p>
<p style="text-indent:-2em;margin-left:6em;">• Coagulopathy</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking</p>
<p style="text-indent:-2em;margin-left:6em;">• Consumption of alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• People with poor general health status</p>
<p style="text-indent:-2em;margin-left:6em;">• Small intestine damage: Small intestine bacterial overgrowth (SIBO), including SIBO induced by proton pump inhibitor therapy, may be associated with an increased risk of small intestine damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052268'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) may result in <b>anemia</b>; drug-induced hemolytic anemia has been reported with use of other NSAIDs, including both non-selective and cyclooxygenase (COX)-2 selective agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25247621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25247621'])">Ref</a></span>). Use of meloxicam may result in a <b>prolonged bleeding time</b> and an increased risk for <b>hemorrhage</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16097928','lexi-content-ref-25004022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16097928','lexi-content-ref-25004022'])">Ref</a></span>); however, nonselective NSAIDs (eg, ibuprofen) may be more likely to impact platelet function and cause prolonged bleeding time compared to selective and relatively selective COX-2 inhibitors (coxibs and meloxicam respectively) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18359332','lexi-content-ref-31961516','lexi-content-ref-11961179','lexi-content-ref-12162470','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18359332','lexi-content-ref-31961516','lexi-content-ref-11961179','lexi-content-ref-12162470','lexi-content-ref-25710657'])">Ref</a></span>). Rarely, NSAID use, including meloxicam, has been associated with potentially severe blood dyscrasias (eg, <b>agranulocytosis</b>, <b>thrombocytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35174032','lexi-content-ref-12974448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35174032','lexi-content-ref-12974448'])">Ref</a></span>), aplastic anemia).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Anemia: Not clearly established; anemia may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis.</p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Inhibition of COX-1 causes a decrease in the production of prostaglandins, prostacyclins, and thromboxanes, including thromboxane A2 (TxA2) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2724096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2724096'])">Ref</a></span>). Therefore, patients exposed to NSAIDs, especially nonselective NSAIDs (eg, naproxen), may exhibit a decrease in platelet adhesion and aggregation and subsequent prolonged bleeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29891025','lexi-content-ref-18193919','lexi-content-ref-19269020','lexi-content-ref-1321554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Prolonged bleeding time: Rapid; suppression of platelet COX-1 activity occurs within hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037526','lexi-content-ref-18359332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037526','lexi-content-ref-18359332'])">Ref</a></span>). In patients receiving antithrombotic therapy after myocardial infarction, the use of NSAIDs, including COX-2 selective NSAIDs, has been associated with an increased risk of bleeding and excess thrombotic events even after short-term treatment (eg, &lt;3 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bleeding events:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting coagulation disorders</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of agents known to increase the risk of bleeding (eg, anticoagulants, antithrombotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>); antiplatelet agents [eg, aspirin], selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>); or serotonin norepinephrine reuptake inhibitors). <i></i></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause mild transaminase elevations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15880319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15880319'])">Ref</a></span>); meloxicam has been associated with both cholestatic and hepatocellular patterns of transaminase elevations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26601797','lexi-content-ref-10427794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26601797','lexi-content-ref-10427794'])">Ref</a></span>). The incidence of hepatic adverse events appears similar between cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs) and nonselective NSAIDs (eg, naproxen, ibuprofen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19530981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19530981'])">Ref</a></span>); diclofenac exhibits a higher rate of hepatotoxic events compared to other NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15880319','lexi-content-ref-29568654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15880319','lexi-content-ref-29568654'])">Ref</a></span>). Rarely, serious liver injury may occur, such as fulminant <b>hepatitis</b>, hepatic necrosis, and/or <b>hepatic failure</b>; meloxicam-induced <b>autoimmune hepatitis</b>, <b>cholestatic hepatitis</b>, <b>hepatotoxicity</b>, and <b>jaundice </b>have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19399620','lexi-content-ref-26601797','lexi-content-ref-10427794','lexi-content-ref-29568654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19399620','lexi-content-ref-26601797','lexi-content-ref-10427794','lexi-content-ref-29568654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; possible mechanisms include a toxic metabolite or a hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19399620','lexi-content-ref-10427794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19399620','lexi-content-ref-10427794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset of NSAID-induced hepatotoxicity is generally classified as moderate (30 to 90 days) to long (&gt;90 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929376'])">Ref</a></span>). For meloxicam, onset was &lt;1 month in a few cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26601797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26601797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prior “oxicam” NSAID (eg, piroxicam)-related liver injury (theoretical risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10427794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10427794'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b> to meloxicam may involve the skin (eg, <b>angioedema</b>, <b>urticaria</b>), airways (eg, <b>dyspnea</b>, rhinorrhea), and/or other organs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15046380','lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15046380','lexi-content-ref-24117484'])">Ref</a></span>). Clinical phenotypes of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions include NSAID-exacerbated respiratory disease (NERD), NSAID-induced urticaria/angioedema (NIUA), NSAID-exacerbated cutaneous disease (NECD), and single NSAID-induced urticaria/angioedema or anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17039673','lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17039673','lexi-content-ref-24117484'])">Ref</a></span>). Delayed hypersensitivity reactions ranging from mild reactions such as <b>fixed drug eruption </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21905514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21905514'])">Ref</a></span>) to more serious reactions including <b>Stevens-Johnson syndrome</b>/<b>toxic epidermal necrolysis </b>(SJS/TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32884758','lexi-content-ref-30129156','lexi-content-ref-22139991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32884758','lexi-content-ref-30129156','lexi-content-ref-22139991'])">Ref</a></span>) have been reported with meloxicam.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Non–dose-related; most reactions (ie, NERD, NECD, NIUA) are non-immunologic related to inhibition of cyclooxygenase (COX)-1 with subsequent activation of mast cells and eosinophils causing release of inflammatory mediators including cysteinyl-leukotrienes (cysLTs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Meloxicam preferentially inhibits COX-2 at lower doses, but at higher doses also inhibits the COX-1 enzyme (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17039673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17039673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768','lexi-content-ref-26339470','lexi-content-ref-29974031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768','lexi-content-ref-26339470','lexi-content-ref-29974031'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur several hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions (including SJS/TEN): Varied, generally occurs after 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-Nice.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-Nice.1'])">Ref</a></span>), although time to onset with meloxicam may be 2 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30129156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30129156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preferential COX-2 inhibitors (eg, meloxicam) are generally tolerated (especially in low to therapeutic doses) in patients with NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33590849','lexi-content-ref-15046380','lexi-content-ref-17016059','lexi-content-ref-17039673','lexi-content-ref-21631520','lexi-content-ref-24388008','lexi-content-ref-17292954','lexi-content-ref-19639736','lexi-content-ref-28049210','lexi-content-ref-32789114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33590849','lexi-content-ref-15046380','lexi-content-ref-17016059','lexi-content-ref-17039673','lexi-content-ref-21631520','lexi-content-ref-24388008','lexi-content-ref-17292954','lexi-content-ref-19639736','lexi-content-ref-28049210','lexi-content-ref-32789114'])">Ref</a></span>) and in many patients with cutaneous reactions to NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33590849','lexi-content-ref-24116718','lexi-content-ref-11488693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33590849','lexi-content-ref-24116718','lexi-content-ref-11488693'])">Ref</a></span>); ~4% to 9% of NECD, NERD, and NIUA patients may develop reactions with meloxicam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17153884','lexi-content-ref-21039786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17153884','lexi-content-ref-21039786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactions with meloxicam and other enolic acid derivatives (“oxicams”) NSAIDs (eg, piroxicam, tenoxicam) may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30663057','lexi-content-ref-11674927']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30663057','lexi-content-ref-11674927'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kidney effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of several kidney-specific effects: hemodynamically-mediated acute kidney injury (AKI), <b>interstitial nephritis</b> (with or without <b>nephrotic syndrome</b>), and <b>renal papillary necrosis</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodynamically-mediated AK): Hemodynamically-mediated AKI may occur following use of either cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs) or nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-25439535','lexi-content-ref-17005625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-25439535','lexi-content-ref-17005625'])">Ref</a></span>); the risk may be greater with nonselective NSAIDs, especially indomethacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26945352','lexi-content-ref-12014386','lexi-content-ref-23633310','lexi-content-ref-10390124'])">Ref</a></span>). The risk of developing AKI is decreased upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>). In patients who develop AKI, kidney function is likely to return to baseline following prompt discontinuation of the offending NSAID and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>); however, the mechanism of the damage and other concurrent factors can contribute to irreversibility.</p>
<p style="text-indent:-2em;margin-left:4em;">Acute interstitial nephritis (AIN) with or without nephrotic syndrome: Patients may develop NSAID-associated proteinuria combined with interstitial nephritis and varying degrees of kidney impairment; the “classic triad” of fever, rash, and eosinophilia is less commonly observed in NSAID-associated AIN than with antibiotic-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6363936','lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>). In patients with concurrent nephrotic syndrome, kidney histology may reveal minimal change glomerulonephritis or membranous nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-31416889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-31416889'])">Ref</a></span>). While use of meloxicam has been associated with this clinical picture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22963504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22963504'])">Ref</a></span>); the risk may be greatest with fenoprofen as compared to other NSAIDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>). Proteinuria generally improves within weeks following discontinuation; full recovery may require treatment and take up to a year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416889','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416889','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Papillary necrosis: Chronic use of NSAIDs has resulted in the development of papillary necrosis which may occur in conjunction with chronic interstitial nephritis and progressive decline in glomerular filtration rate as a clinical syndrome known as analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12512867','lexi-content-ref-7306246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12512867','lexi-content-ref-7306246'])">Ref</a></span>). However, controversy exists on the degree to which NSAID use increases the risk for chronic kidney disease and analgesic nephropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17410098','lexi-content-ref-32317121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17410098','lexi-content-ref-32317121'])">Ref</a></span>). Acute papillary necrosis may occur following NSAID overdose, especially in a setting of severe dehydration or intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodynamically-mediated AKI: Dose- and time-related; inhibition of COX-1 and COX-2 by NSAIDs results in a reduced production of nephroprotective prostaglandins and subsequent attenuation of renal vasodilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3045551','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3045551','lexi-content-ref-10390124'])">Ref</a></span>). In addition, an increase in vasoconstriction of the afferent arteriole and impaired renal blood flow causes a reduction in the glomerular capillary pressure and filtration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Not clearly established. Following inhibition of COX-1 and COX-2 by NSAIDs, arachidonic acid is formed which may be further metabolized to leukotrienes via the lipoxygenase pathway; leukotrienes may increase vascular permeability within glomerular capillaries and peritubular capillaries and increase lymphocyte recruitment and activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Papillary necrosis: Time-related; exact mechanism is not clearly established; may be due to direct toxicity and/or inhibition of prostaglandin-mediated vasodilation resulting in ischemic necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535','lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">AKI: Rapid; may occur within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">AIN with or without nephrotic syndrome: Varied; mean time of onset of ~5 months (range: 2 weeks to 18 months) has been described following use of nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6731494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6731494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:8em;">• AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting kidney impairment</p>
<p style="text-indent:-2em;margin-left:10em;">- Chronic kidney disease; <b>Note:</b> Higher cumulative doses may increase the risk for progression of chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17349452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17349452'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- ≥65 years of age(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31264694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31264694'])">Ref</a></span>); <b>Note: </b>NSAID-associated AKI may also occur in pediatric patients, even at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23453549','lexi-content-ref-23360563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23453549','lexi-content-ref-23360563'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemodynamically-mediated AKI:</p>
<p style="text-indent:-2em;margin-left:10em;">- Preexisting conditions which result in decreased effective arterial circulation (ie, conditions where renal blood flow/renal perfusion may be dependent on prostaglandin-mediated vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Volume depletion (eg, due to concomitant diuretic use, nausea, or vomiting)</p>
<p style="text-indent:-2em;margin-left:12em;">Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Cirrhosis and ascites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-447795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-447795'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:12em;">Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:10em;">- Concomitant use of diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29799625','lexi-content-ref-23299844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29799625','lexi-content-ref-23299844'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• AIN with or without nephrotic syndrome: Prior history of NSAID-induced nephrotic syndrome; recurrence has been described with a nonselective NSAID (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879670'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Papillary necrosis (acute):</p>
<p style="text-indent:-2em;margin-left:10em;">- Massive NSAID ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Intravascular volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21705120','lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21705120','lexi-content-ref-25439535'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Papillary necrosis (chronic)/analgesic nephropathy: Chronic concomitant use of other analgesics (eg, aspirin, acetaminophen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10390124'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F191856"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;2%), angina pectoris (&lt;2%), cardiac arrhythmia (&lt;2%), edema (≤5%), heart failure (&lt;2%), hypertension (&lt;2%), hypotension (&lt;2%), palpitations (&lt;2%), presyncope (&lt;2%), syncope (&lt;2%), tachycardia (&lt;2%), vasculitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;2%), bullous rash (&lt;2%), diaphoresis (&lt;2%), ecchymoses (&lt;2%), pruritus (&lt;2%), skin photosensitivity (&lt;2%), skin rash (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (&lt;2%), dehydration (&lt;2%), hot flash (&lt;2%), hypokalemia (&lt;2%), hypomagnesemia (&lt;2%), weight gain (&lt;2%), weight loss (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;2%), abdominal distress (&lt;2%), abdominal pain (≤3%; more common in pediatric patients), aphthous stomatitis (&lt;2%), colitis (&lt;2%), constipation (8%), diarrhea (≤8%; more common in pediatric patients), duodenal ulcer (&lt;2%; duodenal ulcer with hemorrhage: &lt;2%), dysgeusia (&lt;2%), dyspepsia (6%), epigastric discomfort (&lt;2%), eructation (&lt;2%), esophagitis (&lt;2%), flatulence (&lt;2%), gastric ulcer (&lt;2%; gastric ulcer with hemorrhage: &lt;2%), gastritis (&lt;2%), gastroenteritis (&lt;2%), gastroesophageal reflux disease (&lt;2%), gastrointestinal hemorrhage (&lt;2%), gastrointestinal pain (&lt;2%), gastrointestinal perforation (&lt;2%; including duodenal, gastric), hematemesis (&lt;2%), increased appetite (&lt;2%), intestinal perforation (&lt;2%), melena (&lt;2%), nausea (2% to 4%), pancreatitis (&lt;2%), rectal hemorrhage (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (&lt;2%), pollakiuria (&lt;2%), urinary retention (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (2%)<span class="lexi-table-link-container"> (<a aria-label="Anemia table link" class="lexi-table-link" data-table-id="lexi-content-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anemia')">table 1</a>)</span><span class="table-link" style="display:none;">Anemia</span>, leukopenia (&lt;2%), neutropenia (&lt;2%), prolonged bleeding time (&lt;2%), purpuric disease (&lt;2%), thrombocytopenia (&lt;2%), thrombocytosis (&lt;2%), wound hematoma (IV only: &lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anemia" frame="border" id="lexi-content-anemia" rules="all">
<caption style="text-align:center;">
<b>Meloxicam: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Meloxicam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Meloxicam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IV injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">748</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">393</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (&lt;2%), hepatitis (&lt;2%), hyperbilirubinemia (&lt;2%), increased gamma-glutamyl transferase (≤3%), increased serum alanine aminotransferase (&lt;2%), increased serum aspartate aminotransferase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (&lt;2%), facial edema (&lt;2%), hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Incision-site hemorrhage (IV only: &lt;2%), infusion-site reaction (IV only: &lt;2%), localized rash (IV only, infusion site: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (&lt;2%), anxiety (&lt;2%), asthenia (&lt;2%), confusion (&lt;2%), depression (&lt;2%), disturbance in attention (&lt;2%), dizziness (4%), drowsiness (&lt;2%), falling (3%), fatigue (&lt;2%), headache (2%; more common in pediatric patients), insomnia (&lt;2%), malaise (&lt;2%), migraine (&lt;2%), nervousness (&lt;2%), noncardiac chest pain (&lt;2%), paresthesia (&lt;2%), seizure (&lt;2%), tremor (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&lt;2%), muscle spasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (&lt;2%), increased serum creatinine (&lt;2%), renal failure syndrome (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (&lt;2%), bronchospasm (&lt;2%), dyspnea (&lt;2%), epistaxis (&lt;2%), flu-like symptoms (3% to 6%), pharyngitis (3%), upper respiratory tract infection (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (3% to 5%), fever (&lt;2%; more common in pediatric patients), wound dehiscence (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (more common in pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (Nikas 1999), exfoliative dermatitis, fixed drug eruption (Ozdemir 2011), Stevens-Johnson syndrome (Ishiguro 2020), toxic epidermal necrolysis (Nguyen 2019; Papay 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hemorrhage (Kurien 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Martínez-Odriozola 2010), cholestatic hepatitis (Schmeltzer 2016), hepatic failure, hepatotoxicity (idiosyncratic) (Chalasani 2021), jaundice (Staerkel 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Bavbek 2006), drug reaction with eosinophilia and systemic symptoms (Helmandollar 2018), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Mood changes</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis, nephrotic syndrome (Vega 2012), renal papillary necrosis, renal tubular necrosis (Vega 2012)</p></div>
<div class="block coi drugH1Div" id="F191869"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to meloxicam or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs; use in the setting of coronary artery bypass graft surgery; phenylketonuria (orally disintegrating tablet only); moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion (injection only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy (third trimester); breastfeeding; severe uncontrolled heart failure; active or recent GI/gastric/duodenal/peptic ulceration/perforation; active GI bleeding; cerebrovascular bleeding or other bleeding disorders; inflammatory bowel disease (Crohn disease or ulcerative colitis); severe liver impairment or active liver disease; severe renal impairment (creatinine clearance [CrCl] &lt;30 mL/minute or 0.5 mL/second) or deteriorating renal disease; known hyperkalemia; pediatric patients &lt;18 years; rare hereditary conditions that may be incompatible with an excipient of the product.</p></div>
<div class="block war drugH1Div" id="F191853"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects that may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Non-steroidal anti-inflammatory drug (NSAID) use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE inhibitors). Monitor potassium closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Blurred and/or diminished vision has been reported; discontinue use and refer for ophthalmologic evaluation if such symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac are recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016; Horsley 2019; Thorell 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; patients with hepatic impairment may require reduced doses due to extensive hepatic metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C9 poor metabolizers: Poor metabolizers of CYP2C9 may require dose reduction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Not indicated for long-term use. Onset of pain relief may be delayed up to several hours after administration; use of a non-NSAID analgesic with a rapid onset may be needed. Also, inadequate analgesia for the entire 24-hour dosing interval may be experienced; use of a short-acting, non-NSAID, IR analgesic may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Orally disintegrating tablet: May contain phenylalanine; use is contraindicated in patients with phenylketonuria.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>
<div class="block prod-avail drugH1Div" id="F57442471"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;">Qmiiz ODT has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F191864"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vivlodex: 5 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vivlodex: 10 mg [DSC] [contains carmine, fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anjeso: 30 mg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg/5 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mobic: 7.5 mg [DSC], 15 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg, 15 mg, 15 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qmiiz ODT: 7.5 mg [DSC], 15 mg [DSC] [contains aspartame]</p></div>
<div class="block geq drugH1Div" id="F191849"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F191871"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Meloxicam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $31.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $31.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Meloxicam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/5 mL (per mL): $11.31 - $12.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Meloxicam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $0.05 - $3.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.06 - $4.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867440"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg, 15 mg</p></div>
<div class="block admp drugH1Div" id="F52613235"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken with or without meals; administer with food or milk to minimize gastrointestinal irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet (Qmiiz ODT): Children and Adolescents weighing ≥60 kg: Do not remove from blister until ready to administer. Using dry hands, peel backing off the blister; do not push tablet through foil. Remove tablet and immediately place in mouth or on tongue and allow to disintegrate. Swallow with saliva (with or without drinking liquid).</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake gently prior to use. Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose (overdosage may occur). Administer with or without food.</p></div>
<div class="block adm drugH1Div" id="F9527178"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer undiluted as an IV bolus over 15 seconds.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without meals; administer with food or milk to minimize GI irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Do not remove from blister until ready to administer. Using dry hands, peel backing off the blister; do not push tablet through foil. Remove tablet and immediately place in mouth or on tongue and allow to disintegrate. Swallow with saliva (with or without drinking liquid).</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake oral suspension gently prior to use.</p></div>
<div class="block sts drugH1Div" id="F191882"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 15°C to 25°C (59°F to 77°F); excursions permitted between 4°C to 30°C (40°F to 86°F). Do not freeze. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect tablets and capsules from moisture. Protect orally disintegrating tablets from exposure to excessive heat (40°C [104°F]) and humidity.</p></div>
<div class="block meg drugH1Div" id="F7874886"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Mobic oral suspension: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F021530s017lbl.pdf%23page%3D16&amp;token=v3%2F4hHvGqEbS%2FqrGiLEVw9NRQmZrH1Gfrf0PVKBL8i38zLG7LTNmLnjuLJsEinRPSXGyUZJTr2VCzUuZ4JvHMMNqk2UfwIGaduViIRXVpE0pEq8dJJnPtEt3UMqPrYyz&amp;TOPIC_ID=16017" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021530s017lbl.pdf#page=16</a></p>
<p style="text-indent:-2em;margin-left:4em;">Mobic tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020938s028lbl.pdf%23page%3D16&amp;token=CTrI8XNtO9AyScgNbn87G6Y8zeWn0LV6BifEA%2BNtfJ7rm8%2F17fPXzper%2FSMtd%2FD8VmlewAlkupK3JvFFB%2BOibnI5VnxrFhAiVdYNrAvFFhgy3VPhDuHIORxKF2yauBl4&amp;TOPIC_ID=16017" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020938s028lbl.pdf#page=16</a></p>
<p style="text-indent:-2em;margin-left:4em;">NSAIDs: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F72932%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPIIiK9PLVYV11yGEkp%2BUACZTS4kXFOaY%2F0AyLn2qf5z%2FrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=16017" target="_blank">https://www.fda.gov/media/72932/download</a></p>
<p style="text-indent:-2em;margin-left:4em;">Qmiiz ODT: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F211210s002lbl.pdf%23page%3D37&amp;token=Xdn1KpHVSLrgR0u9CWBjNb%2Bgj6Do8QQjqdt6ntOrzKVI%2BhU%2BC2e12Mg0TmEH6VdkQPZDVDdeLvr9snZmkY9tv2FAH6c6aUMekhVuqBOve21Zyi39GKlpnv3EQsgOVdPS&amp;TOPIC_ID=16017" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211210s002lbl.pdf#page=37</a></p></div>
<div class="block usep drugH1Div" id="F53567677"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets, orally disintegrating tablets (Qmiiz ODT), suspension: Relief of signs and symptoms of pauciarticular or polyarticular course juvenile idiopathic arthritis (JIA) (Suspension: FDA approved in ages ≥2 years and adults; Tablets, orally disintegrating tablets [Qmiiz ODT]: FDA approved in pediatric patients weighing ≥60 kg); relief of signs and symptoms of osteoarthritis and rheumatoid arthritis (all dosage forms: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Management of osteoarthritis pain (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Management of moderate to severe pain alone or in combination with non–nonsteroidal anti-inflammatory drug analgesics (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F14080490"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Meloxicam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided for chronic use in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, avoid for short-term scheduled use in combination with oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents unless alternatives are ineffective and patient can receive concomitant gastroprotective agent (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F191921"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F191858"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Meloxicam may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Meloxicam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May decrease the serum concentration of Meloxicam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.  Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).  Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Meloxicam may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F191874"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Oral: May be taken with food or milk to minimize GI irritation.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308135"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued in males with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F191872"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for meloxicam specifically states use should be avoided starting at 30 weeks' gestation.</p>
<p style="text-indent:0em;margin-top:2em;">Based on available information, NSAIDs can be continued during the first 2 trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases; use in the third trimester is not recommended (ACR [Sammaritano 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53567678"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC and chemistry profile; occult blood loss and periodic liver function tests; renal function (urine output, serum BUN and creatinine); signs or symptoms of GI bleeding; blood pressure; periodic ophthalmologic exam with long-term therapy.</p></div>
<div class="block pha drugH1Div" id="F191852"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>
<p style="text-indent:-2em;margin-left:2em;">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.</p></div>
<div class="block phk drugH1Div" id="F191868"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years (n=7): Oral: Apparent V<sub>d</sub>: Mean: 0.19 L/kg (Burgos-Vargas 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 7 to 16 years (n=11): Oral: Apparent V<sub>d</sub>: Mean: 0.13 L/kg (Burgos-Vargas 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: V<sub>z</sub>: 9.63 L; Oral: Vd<sub>ss</sub>~10 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%, primarily to albumin; <b>Note:</b> Free fraction was higher in adult patients with renal failure who were receiving chronic dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2C9 and CYP3A4 (minor); forms 4 metabolites (inactive).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 89% (capsule).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years (n=7): Oral: Mean: 13.4 hours (Burgos-Vargas 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 7 to 16 years (n=11): Oral: Mean: 12.7 hours (Burgos-Vargas 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: ~24 hours; Oral: ~15 to 22 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 0.12 ± 0.04 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initial: Within 2 hours (capsule); 4 to 5 hours (tablet); 4 to 12 hours (orally disintegrating tablet; prolonged with food); ~7 hours (suspension; following a high-fat meal [75 g of fat]); Secondary: ~8 hours (capsule); 12 to 14 hours (tablet).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (predominantly as inactive metabolites; &lt;1% unchanged drug); feces (predominantly as inactive metabolites; 1.6% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years (n=7): Mean: 0.17 mL/minute/kg (Burgos-Vargas 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 7 to 16 years (n=11): Mean: 0.12 mL/minute/kg (Burgos-Vargas 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 7 to 9 mL/minute.</p></div>
<div class="block phksp drugH1Div" id="F51159445"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: C<sub>max</sub> and AUC increased 5% and 7%, respectively, in elderly subjects with mild renal impairment (eGFR 60 to 90 mL/minute/1.73 m<sup>2</sup>) compared to young healthy controls.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Meloxicam plasma concentration is decreased and total clearance increased in patients with renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869391"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Coxicam | Medoxicam | Meflam | Mel od | Melflam | Melocam | Meloxydar | Mobic | Moven | Neoxicam</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aldoron M | Apo meloxicam | Bronax | Bronax cb | Dominadol | Flexidol | Flexium | Flogoten | Labsycam | Loxitenk | Mell | Meloxicam denver farma | Meloxicam Northia | Meloxicam teva | Mextran | Miogesil | Miolox | Mobic | Nemdol | Skudal | Tenaron | Virobron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam alternova | Meloxicam arcana | Meloxicam G L | Meloxicam interpharm | Meloxicam Ranbaxy | Metosan | Movalis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo meloxicam | Apx meloxicam | Chemmart Meloxicam | Cipla meloxicam | GenRx Meloxicam | Melobic | Melox | Meloxiauro | Meloxibell | Meloxicam an | Meloxicam pfizer | Meloxicam Ranbaxy | Meloxicam sandoz | Mobic | Movalis | Moxicam | Pharmacor Meloxicm | Terry White Chemists Meloxicam | Tw Meloxicam</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Melcam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docmeloxi | Meloxicam Aurobindo Pharma | Meloxicam EG | Meloxicam ratiopharm | Meloxicam sandoz | Meloxicam teva | Mobic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Loximed | Melbek fort | Melox | Movalis | Movix | Noflamen | Recoxa | Trosicam</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alivian | Artritec | Beflox | Bioflac | Cicloxx | Diaden | Dormelox | Flamatec | Inicox | Leutrol | Lonaflam | Loxam | Loxiflan | Melocox | Meloflan | Melotec | Melovac | Meloxigran | Meloxil | Menoxiton | Mevamox | Movacox | Movatec | Movoxicam</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mobicox</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">M cam | Meflam | Mefsal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Anposel | Ecax | Hyflex | Isox | Melic | Melodol | Mexan | Mexilal | Mobex | Tenaron | Zix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">AN LI QING | He chang | Hong qiang | Jie zong | Ke yi | Keyi | Lao guan jian | Luo ke | Mai jie | Mai li ke | Mei er tong | Mo ke lin | Mobic | Qing qing | Sai ke si | Si lai mei | Tong ke | Wu yan | You ni | Ze li</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Algiflex | Artriclox | Artricure | Bienex | Bienex fast | Butazolidina nf | Coxamer | Coxxin | Cronodol forte | Desinbal | Flexidyn | Flexol | Froben | Gesflamar | Henoclox | Impomel x | Inoxicam | Inzelk | Isavan | Lesflis | Leuxicam | Loxac tridex | Loxicam | Mediflex | Melcox | Melocam | Meloflex | Meloxaine | Meltocram | Meprogal | Mevican | Mexican | Mibloc ft | Mobic | Movalis | Mowin | Niflamin | Niflamin pl | Niflamin pl forte | Novoxican | Nulox | Ocam | Rodiflex | Rumonal | Xicandol | Xiclomelan | Xiloxim</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo meloxicam | Artrilom | Melovis | Meloxistad | Movalis | Noflamen | Oramellox | Recoxa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Galoxiway | Meloxicam 1 A Pharma | Meloxicam Aaa | Meloxicam AL | Meloxicam CT | Meloxicam Hexal | Meloxicam ratiopharm | Meloxicam sandoz | Meloxicam stada | Meloxicam Winthrop | Mobec | Mobic | Movalis</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acticam | Alentum | Alidrex | Amix | Bienex | Dicorp | Ilacox | Leutrol | Lexicox | Mecanyl NF | Megaflex | Melatax | Melican | Melocox | Melonax | Melonex | Melosteral | Meloxicam lam | Meloxicam mamey | Meloxil | Mexor | Mibloc ft | Mobicox | Mobicox Vr | Movix | Noragel | Permitil | Rumonal | Suimax | Tenaron</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">15mel | Alivcam | Aremil | Artrox | Autdol | Bienex | Coxamer | Coxicam | Desinflamex | Elocox flash | Flamacoxine | Flexol | Loxem | Loximel | Melbicox | Melixflam | Melocam | Melor | Meloxicam MK | Meloxid | Meloxifem | Meloxigran | Meloxim | Meloxsa | Mibloc ft | Mikalex | Mikalex Direct | Miolox | Mobic | Mowin | Niflamin | Oxa | Oxipan | Tenaron | Trisedam | Xiarax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Melox | Meloxicam ratiopharm | Mexolan | Movalis | Recoxa</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Anti-cox II | Coxicam | Medexaflam | Melocam | Meloflam | Mexicam | Mobic | Mobitil | Moxen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aliviodol | Meloxicam asol | Meloxicam bayvit | Meloxicam bexal | Meloxicam kern | Meloxicam merck | Meloxicam Normon | Meloxicam Pensa | Meloxicam ratiopharm | Meloxicam sandoz | Meloxicam sumol | Movalis | Parocin | Uticox</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Mebilax | Melocam | Melonax</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Latonid | Meloxicam alternova | Meloxicam BMM Pharma | Meloxicam Hexal | Meloxicam Orion | Meloxicam pfizer | Meloxicam ratiopharm | Meloxicam sandoz | Meloxicam teva | Meloxicam Winthrop | Meloxikam Ivax | Mobic</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam Biogaran | Meloxicam EG | Meloxicam pfizer | Meloxicam sandoz | Mobic</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam Almus | Meloxicam Chanelle | Meloxicam Ivax | Meloxicam Kent | Mobic</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Auroxicam | Brosiral | Doctinon | Examel | Farmelox | Iamaxicam | Iaten | Iconal | Infomel | Loxitan | Medoxicam | Melocalm | Melock | Melocox | Melodim | Meloprol | Melorem | Melotec | Melotop | Melox Raldex | Meloxicam/mylan | Meloxicam/SM | Meloxil | Melus | Meomel | Movatec | Movaxin | Notpel | Parogal | Partial | Philipon S | Reumotec | Reumotherm | Saniflam | Starmelox | Supercad | Transantor | Tropofin | Vexicam | Zametrixal | Zerelin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amoria | Apo meloxicam | Arthcam | Melanic | Melcam | Melflam | Melocam | Melocan | Melox | Meloxicam cinfa | Meloxicam stada | Meloxin | Meosicam | Mobic | Moxic | Newsicam | Nulox | Partial | Symelocam | Synloxicam</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Meliam | Movalis</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Borbin | Camelox | Melodyn | Meloxep | Meloxicam pfizer | Meloxicam ratiopharm | Meloxicam teva | Meloxicam Zentiva | Movalis | Moxicam | Noflamen | Trosicam</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Artrilox | Denilox | Flamoxi | Flasicox | Fri art | Futamel | Hexcam | Loxicox | Loxil | Loximei | Loxinic | Mecox | Meflam | Melogra | Meloxin | Mevilox | Mexpharm | Mobiflex | Movicox | Movix | Moxam | Moxic | Ostelox | Paxicam | Relox | Remelox | Rhemacox | Velcox | X-Cam</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Areloger | Melcam | Mobic | Mobicam | Mobiglan | Movox</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Artaz | Ecwin | M cam | Mel od | Melflam | Melo | Meloflam | Melogesic | Melone | Melosuganril | Meloxi | Mexam | Mobix | Movac | Movacam | Movel-old | Muvera | Rafree | Tmel</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Fubic | Meloxicam awa | Movineer | Mubek</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gixal | Leutrol | Meloxicam arrow | Meloxicam EG | Meloxicam Mylan | Meloxicam Ranbaxy | Meloxicam Winthrop | Mobic</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Coxicam | Fixol | Loxicam | Miloxam | Mobic | Motion | Moven | Neo cam | Selektine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam Emec | Meloxicam Kunihiro | Meloxicam Nippon-zoki | Meloxicam towa | Mobic</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Anti-cox II | Benacam | Bettam | Camola | M cam | Mel od | Melbix | Melcam | Melflam | Melgesic | Melonac | Meloxee | Meloz | Mexic | Mobic | Mocam | Mofic | Muvera | Neoxicam | Sucentis | Uxim</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amelox | Amolex | Amoria | Anycox | Aprogen meloxicam | Bomic | Boryung meloxicam | C bic | Camlox | Camrox | Cioex | Cmg Meloxicam | Coxicam | Daewoongbio meloxicam | Exicam | Hamobic | Hamobig | Hanall meloxicam | Huons meloxicam | Icox | Inoxicam | Keibic | Kwangdong meloxicam | Locam | Loxical | Loxicam | Maccam | Mccam | Mebicam | Mecaron | Medicox | Melax | Melbic | Melbicam | Melbigcam | Melbix | Melbrex | Melcam | Melcams | Melcox | Melcoxi | Melica | Melix | Mellox | Melnox | Melo d | Melobic | Meloca m | Melocam | Melocan | Melocap | Melocox | Melodex | Melodin | Melogreen | Melotex | Melotin | Melovic | Melowin | Melox | Meloxam | Meloxcaf | Meloxcam | Meloxi | Meloxica | Meloxid | Meloxifen | Meloxigen | Meloxim | Meloxin | Meloxipen | Meloxt | Melxibic | Memobic | Meranza | Merobic | Merocam | MEROKCAM | Mexi | Moacamxi | Mobex | Mobic | Mobicam | Mobicicam | Mobicox | Mobicxicam | Mobid gju | Mobiden | Mobirocam | Mobixcam | Mocox | Molexel | Moloxcam | Moloxicam | Molvic | Morbic | Morexel | Moricam | Morix | Moscam | Moxicam | Newlocam | Newsicam | Newvic | Pharmabic | Reumel | Samsung meloxicam | Seoul meloxicam | Troxicam | Unicam | Unicox | Woncox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Coxicam | Melgesic | Meloxydar | Mobic | Neoxicam | Rafree</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Loxicam | Miloxam | Mobic | Mobitil | Moven | Neoxicam | Oximal | Penocam | Selektine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lormed | Melobax | Melox | Meloxicam ratiopharm | Meloxicam teva | Meloxistad | Movalis | Noflamen | Normelox | Recoxa</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam Hexal | Meloxicam sandoz | Mobic</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lormed | Melflam | Melobax | Melox | Meloxicam Cipla | Meloxicam ratiopharm | Meloxicam teva | Meloxistad | Mobic | Movalis | Noflamen | Normelox | Recoxa</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aloxia | Artyx | Flamix | Ibermox | Lomax | Mefsal | Melicam | Meloxam | Mobic | Osmal | Raviva | Zenoxia</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aflamid | Anflatox | Anpre | Apocox | Auricam | Dolocam | Exel | Flexiver | Flexol | Indager | Loxam | Loxibach | Masflex | Mavicam | Maxoflam | Meflen | Melhexal | Melican | Melosteral | Meloxicam gi | Meloxicam landsteiner | Menflixil | Mobicox | Nacoflar | Pliris | Promotion | Rafitex | Reosan | Retoflam | Tobansa</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo meloxicam | Aroxicam | Arrox | Avegesic | Dyna meloxicam | Mel od | Melartin | Melflam | Melocam | Melonex | Melox | Meloxim | Mobic | Quicktra | Rafree</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Artrosan | Celomoxicaps | Dabic | Flexaid | Meflex | Melocap | Melorem | Mexpharm | Orthopain | Zilocam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam a | Meloxicam apotex | Meloxicam PCH | Meloxicam ratiopharm | Meloxicam sandoz | Mobic | Movalis | Movicox</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam Actavis | Meloxicam bluefish | Meloxicam BMM Pharma | Meloxicam Mylan | Mobic</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow meloxicam | Melorex | Mobic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Afloxx | Anaxicam | Aremil | Areuma | Artricam | Artriflam | Artrigan | Artritin max | Atiflam | Axius | Bexx | Bioxicam | Cimelox | Coxamer | Coxicam | Dolocam | Dolorit | Dolxicam | Flamelox | Flexaid | Flexol | Flexomycin nf | Flodin | Hynoflex | Ilacox | Isox | Laboxicam | Melbrand | Melixflam | Meloflex | Melonex | Meloxartril | Meloxed | Meloxen | Meloxic | Meloximek | Meloxx | Melsol | Mexifar | Mibloc ft | Mobic | Mowin | Moxicax | Profel | Quimoflan | Talflam | Telaren | Telaren NF | Urzac</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Beramex | Bexxam | Caxlem | Cloxim | Domelox | Eloxim | Flamicxine | Loflam | Loxaid | Loxibic | Meflam | Mel od | Melart | Melcom | Melocam | Melocox | Melofar | Meloflam | Melora | Melox | Meloxicam sandoz | Mexx | Mobic | Newsicam | Osteolax | Pharex Meloxicam | Syloxicam | Teracam | Unicox | Winthrop Meloxicam | Xicam</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abidacam | Altoxicam | Aponip | Armex | Arsocam | Artex | Articam | Artipro | Brilox | Camilox | Coxicam | Coxlan | Eroxx | Freda | Healcam | Jorr | Lexicon | Loxatec | Loxic | Loxicam | Loxidol | Loxigood | Loxitan | M lox | Magix | Mecam | Megit | Mel 2 Cox | Melfax | Melor | Melow | Melox | Meloximed | Meloxistar | Meloxsel | Melpar | Melrun | Mesocam | Metrocam | Mexicam | Mexiran | Mexofin | Micam | Mits | Miws | Miws plus | Mo tu | Mobilex | Mobix | Movera | Mozta | Mubik | Nalcam | Nilem | Orthicam | Osteocam | Oxitic | Ravina | Talgesic | Xetza | Xobix | Xoxilum | Zeloxin | Zoxicam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aglan | Aspicam | Lormed | Mel | Mel forte | Meloksam | Melokssia | Melotev | Meloxic | Meloxicam adamed | Meloxilek | Meloxistad | Moilec | Movalis | Movmax | Opokan | Ortopedina Forte (Meloxicam Arrow 15) | Remolexam | Reumelox | Trosicam</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anjeso | Mobic | Qmiiz odt | Vivlodex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Marlex | Meloxicam APceuticals | Meloxicam aurobindo | Meloxicam Azevedos | Meloxicam bluepharma | Meloxicam Lador | Melpor | Movalis | Ziloxican</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Algioflex | Anaflax | Bexx | Coxifar | Dolimax | Foldox nf | Forenol nf | Huesobone | Hyflex | Letex | Melocox | Meloxicam la sante | Meloxican empa | Mobic | Sinartrol | Supracam | Telarid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aroxicam | Coxicam | Melox | Meloxydar | Mobic | Moven | Neoxicam | Oximal | Selektine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Antrend | Aspiflex | Celomix | Valzer</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amelotex | Bi ksikam | Bi-xikam | Cadimelcox | Exen sanovel | Flexibon | Genitron | Lem | Liberum | M cam | Mataren | Medsikam | Melbek | Meloflam | Melox | Meloxicam akrikhin | Meloxicam Avexima | Meloxicam ds | Meloxicam Obl | Meloxicam pfizer | Meloxicam prana | Meloxicam sandoz | Meloxicam stada | Meloxicam teva | Meloxicam velfarm | Meloxicam vertex | Meloxicam xantis | Mesipol | Mirlox | Mixol OD | Movageyn Express | Movalis | Movasin | Movix | Oxicamox | Revmart</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo meloxicam | Coxicam | Mobic | Neoxicam | Oximal | Pms-meloxicam | Selektine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Meloxicam BMM Pharma | Meloxicam ebb | Meloxicam Hexal | Meloxicam Mylan | Meloxicam teva | Meloxikam MA | Mobic</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Arrox | Melox | Mobic | Nulox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Celomix | Lormed | Meloksikam Arrow | Melokssia | Meloxan | Movalis | Moxicam</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Antrend | Lormed | Meloxan | Meloxicam teva | Meloxikam saneca | Meloxistad | Movalis | Oramellox | Recoxa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cambic | M.p. | Mel od | Melcam | Melobic | Melox | Mobic | Xidane</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Mobic | Moven | Oximal | Xicalm</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Enflar | Exen | Meksun | Melcam | Melox | Melurjin | Mobic | Runomex | Zeloxim</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bon Jour | Loxu | Mecon | Melicam | Melocam | Melox | Meloxicam Shyh Dar | Meloxin | Meosicam | Merocam | Mobic | Mobicam | Mopik | Subic</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Muvera</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Algezicam | Existen sanovel | Loxidol | Melox | Meloxan | Meloxicam kv | Meloxicam ratiopharm | Meloxicam sopharma | Melsi | Movalgin | Movalis | Movixicam odt | Recoxa | Reumalgin | Reumoxicam | Revmoxicamum | Zeloxim</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">M cam | Melonax | Melox | Mobic</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Devincan | Dolcox | Meloxicam Servimedic | Meloxicam teva | Mobic | Nopain | Racotil | Tenaron | Xicane</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Calmox | Mecox | Melocox | Melonax | Melovax | Meloxican | Mobic | Mowin | Pundol | Quicktra | Solican | Taucaron</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Arthrobic | Ausxicam | Bexis | Brawnime | Ceteco melocen | Cophamlox | Coxnis | Fenxicam m | Mealphin | Melgez | Mibelcam fort</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">ADCO Meloxicam | Apex Meloxicam | Arrow meloxicam | Arthrocox | Coxflam | Flamaryx | Flexocam | Glenmark meloxicam | Loxiflam | Medoxicam | Meloxicam Unicorn | Melzy | Mobic</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aroxicam | M cam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35174032">
<a name="35174032"></a>Abdelsayed N, Frost M, Betz WR. Acute isolated thrombocytopenia secondary to meloxicam use: a case report. <i>Cureus</i>. 2022;14(1):e21232. doi:10.7759/cureus.21232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/35174032/pubmed" id="35174032" target="_blank">35174032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation</i>. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6731494">
<a name="6731494"></a>Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. <i>Am J Nephrol</i>. 1984;4(1):1-6. doi:10.1159/000166764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/6731494/pubmed" id="6731494" target="_blank">6731494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891025">
<a name="29891025"></a>Alqahtani Z, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. <i>J Pharm Pharm Sci</i>. 2018;21(1s):29854. doi:10.18433/jpps29854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29891025/pubmed" id="29891025" target="_blank">29891025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baudax.1">
<a name="Baudax.1"></a>Anjeso (meloxicam) [prescribing information]. Malvern, PA: Baudax Bio Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32479922">
<a name="32479922"></a>Baker M, Perazella MA. NSAIDs in CKD: are they safe? <i>Am J Kidney Dis</i>. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/32479922/pubmed" id="32479922" target="_blank">32479922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33590849">
<a name="33590849"></a>Barranco R, Alava C, Garcia-Moguel I, et al. Useful alternative drugs before the use of opioids in patients with allergy to NSAIDs. <i>Rheumatology (Oxford)</i>. 2021;60(6):3025-3026. doi:10.1093/rheumatology/keab165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/33590849/pubmed" id="33590849" target="_blank">33590849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15046380">
<a name="15046380"></a>Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. <i>J Asthma</i>. 2004;41(1):67-75. doi:10.1081/jas-120026063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15046380/pubmed" id="15046380" target="_blank">15046380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17016059">
<a name="17016059"></a>Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. <i>Int Arch Allergy Immunol</i>. 2007;142(1):64-69. doi:10.1159/000096000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17016059/pubmed" id="17016059" target="_blank">17016059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17039673">
<a name="17039673"></a>Bavbek S, Erkekol FO, Dursun B, Misirligil Z. Meloxicam-associated anaphylactic reaction. <i>J Investig Allergol Clin Immunol</i>. 2006;16(5):317-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17039673/pubmed" id="17039673" target="_blank">17039673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al, “The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,” <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30663057">
<a name="30663057"></a>Ben Romdhane H, Ammar H, Ben Fadhel N, et al. Piroxicam-induced fixed drug eruption: cross-reactivity with meloxicam. <i>Contact Dermatitis</i>. 2019;81(1):24-26. doi:10.1111/cod.13225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/30663057/pubmed" id="30663057" target="_blank">30663057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24663106">
<a name="24663106"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340. doi:10.1097/BOR.0000000000000054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24663106/pubmed" id="24663106" target="_blank">24663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8630639">
<a name="8630639"></a>Bevis PJ, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. <i>Br J Rheumatol</i>. 1996;35(suppl 1):56-60. doi:10.1093/rheumatology/35.suppl_1.56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/8630639/pubmed" id="8630639" target="_blank">8630639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726390">
<a name="23726390"></a>Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet</i>. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23726390/pubmed" id="23726390" target="_blank">23726390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682313">
<a name="24682313"></a>Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. <i>World J Surg</i>. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24682313/pubmed" id="24682313" target="_blank">24682313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19017521">
<a name="19017521"></a>Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2008;52(18):1502-1517. doi:10.1016/j.jacc.2008.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/19017521/pubmed" id="19017521" target="_blank">19017521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21705120">
<a name="21705120"></a>Bhave G, Neilson EG. Volume depletion versus dehydration: how understanding the difference can guide therapy. <i>Am J Kidney Dis</i>. 2011;58(2):302-309. doi:10.1053/j.ajkd.2011.02.395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21705120/pubmed" id="21705120" target="_blank">21705120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23558845">
<a name="23558845"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075. doi:10.1213/ANE.0b013e31828a4b54<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23558845/pubmed" id="23558845" target="_blank">23558845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9056050">
<a name="9056050"></a>Boulton-Jones JM, Geddes CG, Heinzel G, Türck D, Nehmiz G, Bevis PJ. Meloxicam pharmacokinetics in renal impairment. <i>Br J Clin Pharmacol</i>. 1997;43(1):35-40. doi:10.1111/j.1365-2125.1997.tb00030.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/9056050/pubmed" id="9056050" target="_blank">9056050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12512867">
<a name="12512867"></a>Brix AE. Renal papillary necrosis. <i>Toxicol Pathol</i>. 2002;30(6):672-674. doi:10.1080/01926230290166760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12512867/pubmed" id="12512867" target="_blank">12512867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23453549">
<a name="23453549"></a>Brophy PD. Changing the paradigm in pediatric acute kidney injury. <i>J Pediatr</i>. 2013;162(6):1094-1096. doi:10.1016/j.jpeds.2013.01.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23453549/pubmed" id="23453549" target="_blank">23453549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286090">
<a name="15286090"></a>Burgos-Vargas R, Foeldvari I, Thon A, et al. Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. <i>J Clin Pharmacol</i>. 2004;44(8):866-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15286090/pubmed" id="15286090" target="_blank">15286090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15037526">
<a name="15037526"></a>Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i>. 2004;109(12):1468-1471. doi:10.1161/01.CIR.0000124715.27937.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15037526/pubmed" id="15037526" target="_blank">15037526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11509629">
<a name="11509629"></a>Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. <i>J Immunol</i>. 2001;167(5):2831-2838. doi:10.4049/jimmunol.167.5.2831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/11509629/pubmed" id="11509629" target="_blank">11509629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16534006">
<a name="16534006"></a>Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. <i>Circulation</i>. 2006;113(12):1578-1587. doi:10.1161/CIRCULATIONAHA.105.595793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/16534006/pubmed" id="16534006" target="_blank">16534006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15110132">
<a name="15110132"></a>Cheng TT, Lai HM, Chiu CK, et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. <i>Clin Ther.</i> 2004;26(3):399-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15110132/pubmed" id="15110132" target="_blank">15110132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11964481">
<a name="11964481"></a>Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. <i>Science</i>. 2002;296(5567):539-541. doi:10.1126/science.1068711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/11964481/pubmed" id="11964481" target="_blank">11964481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945352">
<a name="26945352"></a>Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. <i>Medicine (Baltimore)</i>. 2016;95(9):e2645. doi:10.1097/MD.0000000000002645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26945352/pubmed" id="26945352" target="_blank">26945352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council [published correction appears in <i>J Pain</i>. 2016;17(4):508-510]. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6363936">
<a name="6363936"></a>Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i>. 1984;310(9):563-572. doi:10.1056/NEJM198403013100905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/6363936/pubmed" id="6363936" target="_blank">6363936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24116718">
<a name="24116718"></a>Corzo JL, Zambonino MA, Muñoz C, et al. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Br J Dermatol</i>. 2014;170(3):725-729. doi:10.1111/bjd.12674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24116718/pubmed" id="24116718" target="_blank">24116718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626023">
<a name="9626023"></a>Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. <i>Am J Med</i>. 1998;104(5):413-421. doi:10.1016/s0002-9343(98)00091-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/9626023/pubmed" id="9626023" target="_blank">9626023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29030657">
<a name="29030657"></a>Dalal D, Dubreuil M, Peloquin C, et al. Meloxicam and risk of myocardial infarction: a population-based nested case-control study. <i>Rheumatol Int</i>. 2017;37(12):2071-2078. doi:10.1007/s00296-017-3835-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29030657/pubmed" id="29030657" target="_blank">29030657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31273431">
<a name="31273431"></a>Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/31273431/pubmed" id="31273431" target="_blank">31273431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799625">
<a name="29799625"></a>Delzer LM, Golightly LK, Kiser TH, Biggins SW, Lewis VJ, Kim II. Calcineurin inhibitor and nonsteroidal anti-inflammatory drug interaction: implications of changes in renal function associated with concurrent use. <i>J Clin Pharmacol</i>. 2018;58(11):1443-1451. doi:10.1002/jcph.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29799625/pubmed" id="29799625" target="_blank">29799625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17153884">
<a name="17153884"></a>Domingo MV, Marchuet MJ, Culla MT, Joanpere RS, Guadaño EM. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>J Investig Allergol Clin Immunol</i>. 2006;16(6):364-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17153884/pubmed" id="17153884" target="_blank">17153884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. July 9, 2015. Available at <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/FDA.1/pubmed" id="FDA.1" target="_blank">FDA.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaffo.1">
<a name="Gaffo.1"></a>Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25247621">
<a name="25247621"></a>Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. <i>Immunohematology</i>. 2014;30(2):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/25247621/pubmed" id="25247621" target="_blank">25247621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171810">
<a name="19171810"></a>Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. <i>Arch Intern Med</i>. 2009;169(2):141-149. doi:10.1001/archinternmed.2008.525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/19171810/pubmed" id="19171810" target="_blank">19171810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18359332">
<a name="18359332"></a>Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. <i>Am J Cardiol</i>. 2008;101(7):1060-1063. doi:10.1016/j.amjcard.2007.11.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/18359332/pubmed" id="18359332" target="_blank">18359332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21039786">
<a name="21039786"></a>Göksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. <i>J Dermatol</i>. 2010;37(11):973-979. doi:10.1111/j.1346-8138.2010.00948.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21039786/pubmed" id="21039786" target="_blank">21039786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17349452">
<a name="17349452"></a>Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. <i>Am J Med</i>. 2007;120(3):280.e1-280.e2807. doi:10.1016/j.amjmed.2006.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17349452/pubmed" id="17349452" target="_blank">17349452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15705456">
<a name="15705456"></a>Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. <i>Lancet</i>. 2005;365(9458):475-481. doi:10.1016/S0140-6736(05)17864-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15705456/pubmed" id="15705456" target="_blank">15705456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18541831">
<a name="18541831"></a>Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. <i>Arch Intern Med</i>. 2008;168(11):1219-1224. doi:10.1001/archinte.168.11.1219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/18541831/pubmed" id="18541831" target="_blank">18541831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9783757">
<a name="9783757"></a>Hawkey C, Kahan A, Steinbrück K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. <i>Br J Rheumatol</i>. 1998;37(9):937-945. doi:10.1093/rheumatology/37.9.937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/9783757/pubmed" id="9783757" target="_blank">9783757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30142738">
<a name="30142738"></a>Helmandollar KJ, Hoverson KR, Falkner RC, Meyerle JH. Diffuse vesiculobullous eruption with systemic findings. <i>Dermatol Online J</i>. 2018;24(5):13030/qt09m1x0c1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/30142738/pubmed" id="30142738" target="_blank">30142738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15947398">
<a name="15947398"></a>Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. <i>BMJ</i>. 2005;330(7504):1366. doi:10.1136/bmj.330.7504.1366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15947398/pubmed" id="15947398" target="_blank">15947398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12974448">
<a name="12974448"></a>Hiran S, Mazumdar D, Sarma PS. Acute thrombocytopenic purpura due to meloxicam. <i>J Assoc Physicians India</i>. 2003;51:531-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12974448/pubmed" id="12974448" target="_blank">12974448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18193919">
<a name="18193919"></a>Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(2):129-137. doi:10.2165/00003088-200847020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/18193919/pubmed" id="18193919" target="_blank">18193919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30317488">
<a name="30317488"></a>Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. <i>Obes Surg</i>. 2019;29(2):394-400. doi:10.1007/s11695-018-3526-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/30317488/pubmed" id="30317488" target="_blank">30317488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15754275">
<a name="15754275"></a>Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. <i>Am J Kidney Dis</i>. 2005;45(3):531-539. doi:10.1053/j.ajkd.2004.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15754275/pubmed" id="15754275" target="_blank">15754275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32884758">
<a name="32884758"></a>Ishiguro A, Shibata T, Yanagishita T, et al. A case of drug-induced Stevens-Johnson syndrome-like eruption predominating in mucosa: a case report. <i>Clin Case Rep</i>. 2020;8(8):1379-1381. doi:10.1002/ccr3.2806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/32884758/pubmed" id="32884758" target="_blank">32884758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31961516">
<a name="31961516"></a>Jahr JS, Searle S, McCallum S, et al. Platelet function: meloxicam intravenous in whole blood samples from healthy volunteers. <i>Clin Pharmacol Drug Dev</i>. 2020;9(7):841-848. doi:10.1002/cpdd.772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/31961516/pubmed" id="31961516" target="_blank">31961516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Joshi.1">
<a name="Joshi.1"></a>Joshi GP. Anesthetic management for enhanced recovery after major surgery (ERAS) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2724096">
<a name="2724096"></a>Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. <i>J Pharm Sci</i>. 1989;78(4):324-327. doi:10.1002/jps.2600780413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/2724096/pubmed" id="2724096" target="_blank">2724096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Updated January 2013. Accessed May 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11961179">
<a name="11961179"></a>Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2002;41(4):458-461. doi:10.1093/rheumatology/41.4.458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/11961179/pubmed" id="11961179" target="_blank">11961179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280110">
<a name="24280110"></a>Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. <i>Am J Med</i>. 2014;127(1):53-60.e1. doi:10.1016/j.amjmed.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24280110/pubmed" id="24280110" target="_blank">24280110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117484">
<a name="24117484"></a>Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2013;68(10):1219-1232. doi:10.1111/all.12260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24117484/pubmed" id="24117484" target="_blank">24117484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21631520">
<a name="21631520"></a>Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. <i>Allergy</i>. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21631520/pubmed" id="21631520" target="_blank">21631520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749768">
<a name="25749768"></a>Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? <i>Allergy Asthma Immunol Res</i>. 2015;7(4):312-320. doi:10.4168/aair.2015.7.4.312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/25749768/pubmed" id="25749768" target="_blank">25749768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900801">
<a name="12900801"></a>Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. <i>Am J Kidney Dis</i>. 2003;42(2):217-228. doi:10.1016/s0272-6386(03)00645-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12900801/pubmed" id="12900801" target="_blank">12900801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16097928">
<a name="16097928"></a>Kurien AM. Spontaneous bruising, haematomata and prolonged APTT with meloxicam. <i>Med J Aust</i>. 2005;183(4):219. doi:10.5694/j.1326-5377.2005.tb07006.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/16097928/pubmed" id="16097928" target="_blank">16097928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12014386">
<a name="12014386"></a>Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. <i>Eur J Pediatr</i>. 2002;161(4):202-207. doi:10.1007/s00431-002-0915-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12014386/pubmed" id="12014386" target="_blank">12014386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20955443">
<a name="20955443"></a>Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. <i>Aliment Pharmacol Ther</i>. 2010;32(10):1240-1248. doi:10.1111/j.1365-2036.2010.04465.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/20955443/pubmed" id="20955443" target="_blank">20955443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299844">
<a name="23299844"></a>Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. doi:10.1136/bmj.e8525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23299844/pubmed" id="23299844" target="_blank">23299844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12810929">
<a name="12810929"></a>Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. <i>Rheumatology (Oxford)</i>. 2003;42(11):1332-1341. doi:10.1093/rheumatology/keg376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12810929/pubmed" id="12810929" target="_blank">12810929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20582911">
<a name="20582911"></a>Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. <i>Pharmacoepidemiol Drug Saf</i>. 2010;19(7):708-714. doi:10.1002/pds.1966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/20582911/pubmed" id="20582911" target="_blank">20582911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19399620">
<a name="19399620"></a>Martínez-Odriozola P, Gutiérrez-Macías A, Ibarmia-Lahuerta J, Muñóz-Sánchez J. Meloxicam as a cause of drug-induced autoimmune hepatitis. <i>Dig Dis Sci</i>. 2010;55(4):1191-1192. doi:10.1007/s10620-009-0805-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/19399620/pubmed" id="19399620" target="_blank">19399620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25004022">
<a name="25004022"></a>Martini AK, Rodriguez CM, Cap AP, Martini WZ, Dubick MA. Acetaminophen and meloxicam inhibit platelet aggregation and coagulation in blood samples from humans. <i>Blood Coagul Fibrinolysis</i>. 2014;25(8):831-837. doi:10.1097/MBC.0000000000000162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/25004022/pubmed" id="25004022" target="_blank">25004022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avondale.1">
<a name="Avondale.1"></a>Meloxicam oral suspension [prescribing information]. Birmingham, AL: Avondale Pharmaceuticals LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ranbaxy.1">
<a name="Ranbaxy.1"></a>Meloxicam tablets [prescribing information]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanis.1">
<a name="Sanis.1"></a>Meloxicam tablets [product monograph]. Brampton, Ontario, Canada: Sanis Health Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31416889">
<a name="31416889"></a>Mérida E, Praga M. NSAIDs and nephrotic syndrome. <i>Clin J Am Soc Nephrol</i>. 2019;14(9):1280-1282. doi:10.2215/CJN.08090719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/31416889/pubmed" id="31416889" target="_blank">31416889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360563">
<a name="23360563"></a>Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. <i>J Pediatr</i>. 2013;162(6):1153-1159.e1. doi:10.1016/j.jpeds.2012.11.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23360563/pubmed" id="23360563" target="_blank">23360563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mobic.1">
<a name="Mobic.1"></a>Mobic (meloxicam) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879670">
<a name="10879670"></a>Mohammed EP, Stevens JM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. <i>Clin Nephrol</i>. 2000;53(6):483-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/10879670/pubmed" id="10879670" target="_blank">10879670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24388008">
<a name="24388008"></a>Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. <i>J Allergy Clin Immunol</i>. 2014;134(1):40-45. doi:10.1016/j.jaci.2013.10.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24388008/pubmed" id="24388008" target="_blank">24388008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078175">
<a name="11078175"></a>Morgan TO, Anderson A, and Bertram D, “Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,” <i>Am J Hypertens</i>, 2000, 13(11):1161-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/11078175/pubmed" id="11078175" target="_blank">11078175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31264694">
<a name="31264694"></a>Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. <i>Nephrol Dial Transplant</i>. 2019;34(7):1145-1154. doi:10.1093/ndt/gfz062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/31264694/pubmed" id="31264694" target="_blank">31264694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nice.1">
<a name="Nice.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. Published September 3, 2014. Accessed April 12, 2022. www.nice.org.uk/guidance/cg183.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11488693">
<a name="11488693"></a>Nettis E, Di Paola R, Ferrannini A, Tursi A. Meloxicam in hypersensitivity to NSAIDs. <i>Allergy</i>. 2001;56(8):803-804. doi:10.1034/j.1398-9995.2001.056008803.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/11488693/pubmed" id="11488693" target="_blank">11488693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30129156">
<a name="30129156"></a>Nguyen KD, Tran TN, Nguyen MT, et al. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: a subgroup approach to disproportionality analysis. <i>J Clin Pharm Ther</i>. 2019;44(1):69-77. doi:10.1111/jcpt.12754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/30129156/pubmed" id="30129156" target="_blank">30129156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959716">
<a name="27959716"></a>Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. <i>N Engl J Med</i>. 2016;375(26):2519-2529. doi:10.1056/NEJMoa1611593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/27959716/pubmed" id="27959716" target="_blank">27959716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3045551">
<a name="3045551"></a>Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). <i>N Engl J Med</i>. 1988;319(12):761-767. doi:10.1056/NEJM198809223191206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/3045551/pubmed" id="3045551" target="_blank">3045551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23633310">
<a name="23633310"></a>Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. <i>Cochrane Database Syst Rev</i>. 2013;(4):CD003481. doi:10.1002/14651858.CD003481.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23633310/pubmed" id="23633310" target="_blank">23633310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28052268">
<a name="28052268"></a>Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. <i>Digestion</i>. 2017;95(1):22-28. doi:10.1159/000452356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/28052268/pubmed" id="28052268" target="_blank">28052268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21905514">
<a name="21905514"></a>Ozdemir SK, Erkekol FO, Aydin O, Celik GE, Misirligil Z. Fixed drug eruption due to meloxicam. <i>J Investig Allergol Clin Immunol</i>. 2011;21(5):419-420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21905514/pubmed" id="21905514" target="_blank">21905514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16469671">
<a name="16469671"></a>Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of <i>Helicobacter pylori</i> and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. <i>Clin Gastroenterol Hepatol</i>. 2006;4(2):130-142. doi:10.1016/j.cgh.2005.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/16469671/pubmed" id="16469671" target="_blank">16469671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139991">
<a name="22139991"></a>Papay J, Yuen N, Powell G, Mockenhaupt M, Bogenrieder T. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. <i>Pharmacoepidemiol Drug Saf</i>. 2012;21(3):289-296. doi:10.1002/pds.2276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/22139991/pubmed" id="22139991" target="_blank">22139991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2012355">
<a name="2012355"></a>Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. <i>Ann Intern Med</i>. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/2012355/pubmed" id="2012355" target="_blank">2012355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17292954">
<a name="17292954"></a>Prieto A, De Barrio M, Martín E, et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. <i>J Allergy Clin Immunol</i>. 2007;119(4):960-964. doi:10.1016/j.jaci.2006.12.616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17292954/pubmed" id="17292954" target="_blank">17292954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>
<i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 7th ed. American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qmiiz.1">
<a name="Qmiiz.1"></a>Qmiiz ODT (meloxicam) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19639736">
<a name="19639736"></a>Quiñones Estévez MD. Are selective COX-2 inhibitors a safe option in patients with intolerance to nonsteroidal antiinflammatory drugs? <i>J Investig Allergol Clin Immunol</i>. 2009;19(4):328-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/19639736/pubmed" id="19639736" target="_blank">19639736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439535">
<a name="25439535"></a>Rahman S, Malcoun A. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. <i>Prim Care</i>. 2014;41(4):803-821. doi:10.1016/j.pop.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/25439535/pubmed" id="25439535" target="_blank">25439535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20031832">
<a name="20031832"></a>Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. <i>Circ Cardiovasc Qual Outcomes</i>. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/20031832/pubmed" id="20031832" target="_blank">20031832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28049210">
<a name="28049210"></a>Rebelo Gomes E, Geraldes L, Gaspar Â, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs among adults: clinical features and risk factors for diagnosis confirmation. <i>Int Arch Allergy Immunol</i>. 2016;171(3-4):269-275. doi:10.1159/000452627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/28049210/pubmed" id="28049210" target="_blank">28049210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12162470">
<a name="12162470"></a>Rinder HM, Tracey JB, Souhrada M, Wang C, Gagnier RP, Wood CC. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. <i>J Clin Pharmacol</i>. 2002;42(8):881-886. doi:10.1177/009127002401102795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12162470/pubmed" id="12162470" target="_blank">12162470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15880319">
<a name="15880319"></a>Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. <i>Clin Gastroenterol Hepatol</i>. 2005;3(5):489-498. doi:10.1016/s1542-3565(04)00777-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15880319/pubmed" id="15880319" target="_blank">15880319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17556027">
<a name="17556027"></a>Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. <i>Clin Gastroenterol Hepatol</i>. 2007;5(7):818-768. doi:10.1016/j.cgh.2007.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17556027/pubmed" id="17556027" target="_blank">17556027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692986">
<a name="15692986"></a>Ruperto N, Nikishina I, Pachanov ED, et al, "A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis: Short- and Long-Term Efficacy and Safety Results," <i>Arthritis Rheum</i>, 2005, 52(2):563-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15692986/pubmed" id="15692986" target="_blank">15692986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020251">
<a name="29020251"></a>Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. <i>Eur Heart J</i>. 2017;38(44):3282-3292. doi:10.1093/eurheartj/ehx508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29020251/pubmed" id="29020251" target="_blank">29020251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19269020">
<a name="19269020"></a>Schjerning O, Larsen TB, Damkier P. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thromb Res</i>. 2009;124(2):208-212. doi:10.1016/j.thromres.2009.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/19269020/pubmed" id="19269020" target="_blank">19269020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24690187">
<a name="24690187"></a>Schjerning Olsen AM, Fosbøl EL, Gislason GH. The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data. <i>Basic Clin Pharmacol Toxicol</i>. 2014;115(2):179-184. doi:10.1111/bcpt.12244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/24690187/pubmed" id="24690187" target="_blank">24690187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555710">
<a name="21555710"></a>Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. <i>Circulation</i>. 2011;123(20):2226-2235. doi:10.1161/CIRCULATIONAHA.110.004671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21555710/pubmed" id="21555710" target="_blank">21555710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710657">
<a name="25710657"></a>Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA</i>. 2015;313(8):805-814. doi:10.1001/jama.2015.0809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/25710657/pubmed" id="25710657" target="_blank">25710657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26601797">
<a name="26601797"></a>Schmeltzer PA, Kosinski AS, Kleiner DE, et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. <i>Liver Int</i>. 2016;36(4):603-609. doi:10.1111/liv.13032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26601797/pubmed" id="26601797" target="_blank">26601797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17005625">
<a name="17005625"></a>Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. <i>Am J Epidemiol</i>. 2006;164(9):881-889. doi:10.1093/aje/kwj331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17005625/pubmed" id="17005625" target="_blank">17005625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10628593">
<a name="10628593"></a>Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. <i>Am J Med</i>. 1999;107(6A):48S-54S. doi:10.1016/s0002-9343(99)00367-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/10628593/pubmed" id="10628593" target="_blank">10628593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mariano.1">
<a name="Mariano.1"></a>Schwenk ES. Nonopioid pharmacotherapy for acute pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7306246">
<a name="7306246"></a>Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. <i>Arthritis Rheum</i>. 1981;24(9):1208-1210. doi:10.1002/art.1780240917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/7306246/pubmed" id="7306246" target="_blank">7306246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234645">
<a name="15234645"></a>Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. <i>Am J Med</i>. 2004;117(2):100-106. doi:10.1016/j.amjmed.2004.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/15234645/pubmed" id="15234645" target="_blank">15234645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19530981">
<a name="19530981"></a>Soni P, Shell B, Cawkwell G, Li C, Ma H. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. <i>Curr Med Res Opin</i>. 2009;25(8):1841-1851. doi:10.1185/03007990903018279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/19530981/pubmed" id="19530981" target="_blank">19530981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29568654">
<a name="29568654"></a>Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. <i>Int J Hepatol</i>. 2018;2018:5253623. doi:10.1155/2018/5253623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29568654/pubmed" id="29568654" target="_blank">29568654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10427794">
<a name="10427794"></a>Staerkel P, Horsmans Y. Meloxicam-induced liver toxicity. <i>Acta Gastroenterol Belg</i>. 1999;62(2):255-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/10427794/pubmed" id="10427794" target="_blank">10427794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26925883">
<a name="26925883"></a>Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi:10.1038/ajg.2016.41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26925883/pubmed" id="26925883" target="_blank">26925883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31937550">
<a name="31937550"></a>Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i>. 2020;69(4):617-629. doi:10.1136/gutjnl-2019-319300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/31937550/pubmed" id="31937550" target="_blank">31937550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32789114">
<a name="32789114"></a>Terzioğlu K, Sancar Ö, Ekerbiçer HÇ, Öztürk RT, Epöztürk K. Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity. <i>Asia Pac Allergy</i>. 2020;10(3):e29. doi:10.5415/apallergy.2020.10.e29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/32789114/pubmed" id="32789114" target="_blank">32789114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943657">
<a name="26943657"></a>Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. <i>World J Surg</i>. 2016;40(9):2065-2083. doi:10.1007/s00268-016-3492-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/26943657/pubmed" id="26943657" target="_blank">26943657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21224324">
<a name="21224324"></a>Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. <i>BMJ</i>. 2011;342:c7086. doi:10.1136/bmj.c7086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/21224324/pubmed" id="21224324" target="_blank">21224324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11674927">
<a name="11674927"></a>Trujillo MJ, de Barrio M, Rodríguez A, et al. Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report. <i>Allergol Immunopathol (Madr)</i>. 2001;29(4):133-136. doi:10.1016/s0301-0546(01)79046-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/11674927/pubmed" id="11674927" target="_blank">11674927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9010704">
<a name="9010704"></a>Türck D, Schwarz A, Höffler D, Narjes HH, Nehmiz G, Heinzel G. Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. <i>Eur J Clin Pharmacol</i>. 1996;51(3-4):309-313. doi:10.1007/s002280050203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/9010704/pubmed" id="9010704" target="_blank">9010704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 15, 2020. Accessed October 20, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/FDA.2/pubmed" id="FDA.2" target="_blank">FDA.2</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17410098">
<a name="17410098"></a>Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. <i>Kidney Int</i>. 2007;72(4):517-520. doi:10.1038/sj.ki.5002251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/17410098/pubmed" id="17410098" target="_blank">17410098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22963504">
<a name="22963504"></a>Vega J, Goecke H, Méndez GP, Guarda FJ. Nephrotic syndrome and acute tubular necrosis due to meloxicam use. <i>Ren Fail</i>. 2012;34(10):1344-1347. doi:10.3109/0886022X.2012.718953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/22963504/pubmed" id="22963504" target="_blank">22963504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1321554">
<a name="1321554"></a>Villanueva M, Heckenberger R, Palmér M, Schrör K. Stereospecific and non-stereospecific effects of ibuprofen on human platelet and polymorphonuclear leukocyte functions. <i>Agents Actions Suppl</i>. 1992;37:162-170. doi:10.1007/978-3-0348-7262-1_22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/1321554/pubmed" id="1321554" target="_blank">1321554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Egalet.1">
<a name="Egalet.1"></a>Vivlodex (meloxicam) [prescribing information]. Wayne, PA: Egalet US Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10377455">
<a name="10377455"></a>Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. <i>Proc Natl Acad Sci U S A</i>. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/10377455/pubmed" id="10377455" target="_blank">10377455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12020179">
<a name="12020179"></a>Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. <i>Arch Intern Med</i>. 2002;162(10):1105-1110. doi:10.1001/archinte.162.10.1105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/12020179/pubmed" id="12020179" target="_blank">12020179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390124">
<a name="10390124"></a>Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. <i>Am J Med</i>. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/10390124/pubmed" id="10390124" target="_blank">10390124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29974031">
<a name="29974031"></a>Wöhrl S. NSAID hypersensitivity - recommendations for diagnostic work up and patient management. <i>Allergo J Int</i>. 2018;27(4):114-121. doi:10.1007/s40629-018-0064-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/29974031/pubmed" id="29974031" target="_blank">29974031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23747642">
<a name="23747642"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/23747642/pubmed" id="23747642" target="_blank">23747642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32317121">
<a name="32317121"></a>Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. <i>Am J Kidney Dis</i>. 2020;76(2):184-193. doi:10.1053/j.ajkd.2019.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/32317121/pubmed" id="32317121" target="_blank">32317121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-447795">
<a name="447795"></a>Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. <i>J Clin Endocrinol Metab</i>. 1979;48(6):895-900. doi:10.1210/jcem-48-6-895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/meloxicam-pediatric-drug-information/abstract-text/447795/pubmed" id="447795" target="_blank">447795</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16017 Version 590.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
